Skip to main content

Advertisement

Table 2 Patient treatment history for anti-CTLA-4 and anti-PD-1 treated patients

From: Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients

Anti-CTLA-4 patients treatment history
  Total patients Treatment naïve Treatment experienced Checkpoint blockade experienced
Responders 10 10 0 0
Non-responders 14 8 6 0
Total patients 24 18 6 0
Anti-CTLA-4 patients treatment experienced
  Treatment experienced Ave. months between end of prior treatment and anti-CTLA-4 therapy Range (months)
Responders 0 N/A N/A
Non-responders 6 2.5 < 1~ 11
Anti-PD-1 patients treatment history
  Total patients Treatment naive Treatment experienced Checkpoint blockade experienced Nivolumab experienced
Responders 21 8 13 12 1
Non-responders 19 6 13 11 2
Total patients 40 14 26 23 3
Anti-PD-1 patients treatment experienced
  Treatment experienced Ave. months between end of prior treatment and anti-PD-1 therapy STDEV (months) U test p value between groups
Responders 13 6.3 7.1 0.59
Non-responders 13 4.5 6.6
  1. The above tables list the number of patients who were treatment naïve and treatment experienced in either the anti-CTLA-4 or anti-PD-1 cohort. In the anti-CTLA-4 cohort, 6 out of 24 patients were treatment experienced. None of them had experienced prior checkpoint blockade therapies. The average and range of time window (months) from end of prior therapy of any kind and start of anti-CTLA-4 are shown. Among anti-PD-1 patients, the majority of treatment experienced patients had prior checkpoint blockade therapies (23/26). Of these, 3 had prior nivolumab (in combination or sequential therapies with ipilimumab and other modalities). The average time window (months) from end of prior therapy of any kind and start of anti-PD-1 in both responders and non-responders are shown. Standard deviation of the time window in responders and non-responders are listed. Mann-Whitney U test was used to compare responders and non-responders